WuXi Biology provides a full spectrum of services and solutions to support stand-alone and integrated projects, from target discovery to candidate selection and into the clinic. Our world-class discovery platform is backed by nearly 3000 scientists, offering expertise in all major disease areas and target classes, across all therapeutic modalities. From small molecules, peptides, oligonucleotides to biologics, our state-of-the-art services, quick study launches and fast turnaround times meet the diverse needs of our clients.

WuXi AppTec’s Laboratory Testing Division provides comprehensive, globally integrated CRDMO-enabling solutions for pharmaceutical companies advancing small molecules, biologics, and emerging therapeutic modalities. The division delivers end-to-end DMPK services, safety assessments, and bioanalytical support throughout the development pipeline. With extensive experience in novel compound classes including PROTACs, oligonucleotides, and ADCs, the team combines scientific expertise, deep regulatory insight, and operational agility to accelerate drug development timelines.